<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Albilali, Abdulrazaq S.</style></author><author><style face="normal" font="default" size="100%">Alkawi, Ammar M.</style></author><author><style face="normal" font="default" size="100%">Alotaibi, Naser D.</style></author><author><style face="normal" font="default" size="100%">Qureshi, Shireen AM.</style></author><author><style face="normal" font="default" size="100%">Alabdali, Majed M.</style></author><author><style face="normal" font="default" size="100%">Alabdaly, Hani M.</style></author><author><style face="normal" font="default" size="100%">Alenzi, Bader A.</style></author><author><style face="normal" font="default" size="100%">Al Khathaami, Ali M.</style></author><author><style face="normal" font="default" size="100%">Elchami, Ziad M.</style></author><author><style face="normal" font="default" size="100%">Alesefir, Walid A.</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Migraine management in Saudi Arabia: An expert consensus</style></title><secondary-title><style face="normal" font="default" size="100%">Neurosciences Journal</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2025-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">169-176</style></pages><doi><style  face="normal" font="default" size="100%">10.17712/nsj.2025.3.20240118</style></doi><volume><style face="normal" font="default" size="100%">30</style></volume><issue><style face="normal" font="default" size="100%">3</style></issue><abstract><style  face="normal" font="default" size="100%">Objective: To establish expert consensus on the preventive treatment of migraine in Saudi Arabia, with a focus on the use of calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs), in light of the latest international guidelines and local clinical practice.Method: A panel of 10 neurologists and headache specialists from various regions in Saudi Arabia convened virtually to evaluate the latest evidence and clinical experience with migraine preventive treatments. A web-based questionnaire containing evidence-based and practice-driven statements was distributed among the panel. Statements that received ≥70% agreement were considered to have reached consensus. A final set of consensus recommendations was drafted and validated by all panel members.Results: The expert panel reviewed updated clinical data and recent international guidelines recommending CGRP mAbs as first-line preventive treatment options. The panel reached consensus on key aspects of migraine management in Saudi Arabia, including treatment initiation criteria, patient selection, and the role of CGRP mAbs in clinical practice. The recommendations emphasize the need for earlier initiation of effective treatments to reduce disease burden and improve quality of life.Conclusion: This expert consensus provides updated guidance on the preventive treatment of migraine in Saudi Arabia, supporting the integration of CGRP mAbs as a first-line option. These recommendations aim to enhance the standard of migraine care and address unmet needs in the local healthcare setting.</style></abstract></record></records></xml>